Business Week -- Genetic test makers are defending their fledgling industry and arguing the benefits of marketing their disease-predicting kits directly to consumers before regulators from the Food and Drug Administration. The two-day meeting will shape the regulation of technology that has attracted millions of dollars in venture capital investments, as well as skepticism from doctors and scientists.
